Justin Waite on X: ""Upon FDA approval (90% probability), we value Polarean #POLX at 135p per share on a risk-adjusted NPV basis, which implies c.50% upside to the current share price, hence
Polarean shares jump after unveiling collaboration with Philips -June 02, 2023 at 02:36 pm EDT | MarketScreener